GSK announced that it will recall more than 593,000 Ventolin asthma inhalers in the United States voluntarily. Because of a defect that may cause the inhalers to deliver fewer doses than indicated, GSK will pull the inhalers from hospitals, pharmacies, retailers and wholesalers in the U.S.
The recall affects three Ventolin HFA 200D inhaler lots that were manufactured in Zebulon, North Carolina. According to Teva, complaints about the outside wrapper bulging, which suggest a propellant leak, have been up. The company also reported that the FDA approved the "Level 2" recall, which is limited to products in the U.S.
Read the Reuters report